COPENHAGEN, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Zealand Pharma (Copenhagen:ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces the appointment of a new Clinical and Scientific Advisory Board (the CSAB). The CSAB comprises internationally renowned scientific and clinical advisors in the fields of diabetes and obesity, cardiology and gastroenterology to reflect the therapeutic focus of Zealand Pharma's research and development activities.
